New Lifetime High Reached By Revance Therapeutics (RVNC)
Trade-Ideas LLC identified
(
) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Revance Therapeutics as such a stock due to the following factors:
- RVNC has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $46.5 million.
- RVNC has traded 21,538 shares today.
- RVNC is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in RVNC with the Ticky from Trade-Ideas. See the FREE profile for RVNC NOW at Trade-Ideas
More details on RVNC:
Revance Therapeutics, Inc., a clinical-stage specialty biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. Currently there are 3 analysts that rate Revance Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for Revance Therapeutics has been 304,400 shares per day over the past 30 days. Revance has a market cap of $884.7 million and is part of the health care sector and drugs industry. Shares are up 113.4% year-to-date as of the close of trading on Monday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Revance Therapeutics as a
. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and disappointing return on equity.
Highlights from the ratings report include:
- REVANCE THERAPEUTICS INC's earnings per share declined by 35.0% in the most recent quarter compared to the same quarter a year ago. Earnings per share have declined over the last year. We anticipate that this should continue in the coming year. During the past fiscal year, REVANCE THERAPEUTICS INC reported poor results of -$3.10 versus -$0.57 in the prior year. For the next year, the market is expecting a contraction of 15.2% in earnings (-$3.57 versus -$3.10).
- The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Pharmaceuticals industry average. The net income has significantly decreased by 37.2% when compared to the same quarter one year ago, falling from -$13.98 million to -$19.18 million.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, REVANCE THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Despite the stagnant revenue growth, the company outperformed against the industry average of 3.8%. Since the same quarter one year prior, revenues have remained constant. Even though the company's revenue remained stagnant, the earnings per share decreased.
- RVNC's debt-to-equity ratio is very low at 0.06 and is currently below that of the industry average, implying that there has been very successful management of debt levels.
- You can view the full Revance Therapeutics Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.